Generate a tailored SOP for Dr. Tim Denison. Improve your application with a focused, well-structured draft.
Professor Denison holds the Royal Academy Engineering Chair in Emerging Technologies at the University of Oxford, where he explores the fundamentals of physiologic closed-loop systems. Before joining Oxford, he was Vice President of Research & Core Technology at Medtronic, supervising the design and generation of neural interface algorithm technologies for treating neurological disorders. Awarded membership in the Bakken Society in 2012, Medtronic’s highest scientific honor, in 2014 he received the Wallin Leadership Award and became the only person in Medtronic’s history to achieve both awards. He became a Fellow of the American Institute of Medical and Biological Engineering in 2015. Since moving to the UK in 2018, he has focused on “brain engineering” and was named a Fellow of the Royal Academy of Engineering in 2024 due to his contributions to research systems and investigational devices in clinical neuroscience for new neurological disorder treatments. Tim is the co-founder and chief engineer of Amber Therapeutics, applying research tools to mixed urinary incontinence and supporting various academic studies focused on central and peripheral nervous system diseases. His work has led to hundreds of issued patents across multiple fields, including gene sequencing and brain-computer interfaces.
University of Oxford • Oxford, UK
Holds the Royal Academy Engineering Chair in Emerging Technologies at the Institute of Biomedical Engineering.
Medtronic • USA
Supervised design and development of neural interface technologies for treating neurological disorders.
Department of Politics and International Relations - Higher Level English requirement.